Molecular Imaging Market Size, Share, Growth, and Industry Analysis, By Type (PSMA PET Imaging, FDG PET Imaging, Other), By Application (Oncology, Cardiovascular Diseases, Neurology, Respiratory Diseases, Others), Regional Insights and Forecast to 2035

Unique Information about the Molecular Imaging Market

Molecular Imaging Market size is anticipated to be worth USD 9345.79 million in 2026 and is expected to reach USD 48064.91 million by 2035 at a CAGR of 19.96%.

The global Molecular Imaging Market is expanding due to rising adoption of hybrid imaging systems and precision diagnostics across oncology, neurology, and cardiology. More than 45% of advanced hospitals globally integrated PET/CT systems into routine cancer diagnostics during 2024, while over 31 million PET scans were conducted worldwide. Molecular imaging procedures account for nearly 38% of advanced diagnostic imaging for cancer staging. Around 72% of radiopharmaceutical utilization is linked to oncology applications, while neurological applications contribute approximately 14%. More than 8,500 PET imaging centers are operational globally, with over 63% located in developed economies. Molecular Imaging Market Trends indicate increasing installation of AI-enabled imaging systems with image reconstruction efficiency improving by 28%.

The United States accounts for nearly 41% of global molecular imaging procedure volumes, supported by more than 2,400 PET/CT installations and over 220 cyclotron facilities. Approximately 19 million nuclear medicine imaging procedures are conducted annually across the country, with oncology representing nearly 74% of total molecular imaging applications. More than 67% of hospitals with over 300 beds use hybrid molecular imaging systems for cancer diagnosis and therapy planning. FDG PET imaging utilization increased by 24% between 2022 and 2024 in the United States. Molecular Imaging Industry Analysis shows that over 58% of radiologists in tertiary hospitals rely on AI-supported molecular imaging platforms for improved lesion detection accuracy.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: More than 73% of oncology diagnostic centers increased molecular imaging adoption, while 61% of physicians preferred PET-based diagnosis for early-stage cancer detection and nearly 54% of healthcare facilities expanded nuclear imaging infrastructure during 2024.
• Major Market Restraint: Approximately 48% of small healthcare facilities reported limited access to PET imaging systems, while 44% cited high installation complexity and 39% identified shortages of trained nuclear medicine professionals affecting adoption rates.
• Emerging Trends: Around 66% of imaging manufacturers integrated AI-assisted imaging analytics into molecular imaging systems, while 58% of hospitals adopted hybrid PET/MRI technologies and 46% expanded theranostic imaging applications during 2024.
• Regional Leadership: North America contributed nearly 39% of global molecular imaging procedure volumes, while Europe accounted for 28%, Asia-Pacific represented 24%, and Middle East & Africa contributed approximately 9% during 2024.
• Competitive Landscape: Nearly 57% of the Molecular Imaging Market Share remained concentrated among the top five imaging technology manufacturers, while 43% of healthcare facilities preferred integrated PET/CT platforms from multinational suppliers.
• Market Segmentation: PET imaging technologies represented approximately 64% of total molecular imaging installations, while oncology applications contributed nearly 72% of overall imaging utilization and neurology accounted for around 13% globally.
• Recent Development: More than 36% of newly launched molecular imaging systems between 2023 and 2025 included AI-based reconstruction software, while PET tracer development activity increased by 29% among leading manufacturers.

Molecular Imaging Market Latest Trends

The Molecular Imaging Market is experiencing rapid transformation due to advancements in hybrid imaging modalities, AI integration, and radiopharmaceutical innovations. PET/CT systems currently account for approximately 68% of hybrid molecular imaging installations globally, while PET/MRI systems represent around 11% of new high-end imaging deployments. More than 62% of tertiary hospitals adopted digital PET technologies during 2024 to improve lesion sensitivity and image clarity. Molecular Imaging Market Insights indicate that image acquisition times declined by nearly 34% with digital detector technologies.

AI-assisted imaging interpretation emerged as a significant trend, with over 59% of imaging centers implementing machine learning algorithms for image reconstruction and tumor segmentation. Approximately 47% of radiologists reported improved diagnostic confidence through AI-supported molecular imaging software. Theranostics adoption increased by 41% between 2023 and 2025, especially in prostate cancer imaging involving PSMA PET scans. Radiopharmaceutical innovation also accelerated, with over 95 new tracer studies initiated globally during 2024. FDG tracers still dominate with nearly 69% share of total tracer utilization, while PSMA tracers reached approximately 18% share in oncology imaging. Molecular Imaging Market Forecast data shows increasing demand for personalized diagnostics supported by precision medicine programs across more than 52 countries.

Molecular Imaging Market Dynamics

DRIVER

"Rising demand for precision oncology diagnostics"

The increasing prevalence of cancer significantly drives Molecular Imaging Market Growth. More than 20 million new cancer cases were diagnosed globally in 2024, while nearly 72% of oncologists recommended PET-based molecular imaging for advanced tumor characterization. Approximately 64% of hospitals expanded molecular imaging capabilities to support personalized treatment planning. PET imaging improves tumor localization accuracy by nearly 33% compared to conventional imaging methods. In oncology clinical trials, molecular imaging technologies are utilized in approximately 58% of biomarker-driven studies. The rise of targeted radiopharmaceuticals also contributed to higher procedure volumes, especially for prostate and neuroendocrine cancers. Molecular Imaging Market Research Report findings indicate that over 46% of cancer centers invested in hybrid imaging systems to enhance diagnostic workflow efficiency.

RESTRAINT

"Limited access to radiopharmaceutical infrastructure"

Infrastructure limitations remain a major restraint in the Molecular Imaging Industry Report. Nearly 42% of developing economies lack sufficient cyclotron facilities for isotope production, while 37% of imaging centers reported irregular radiotracer supply chains. PET imaging installation requires shielding and radiation compliance infrastructure, increasing operational complexity. Around 49% of smaller diagnostic centers depend on outsourced radiopharmaceutical distribution networks. Skilled workforce shortages also affect adoption, with approximately 33% of nuclear medicine departments reporting staffing gaps. Regulatory compliance timelines for radiopharmaceutical approvals exceed 18 months in several regions, slowing commercialization. Molecular Imaging Market Analysis highlights that maintenance costs for advanced PET/MRI systems are approximately 27% higher than standard imaging equipment.

OPPORTUNITY

"Expansion of theranostics and personalized medicine"

Theranostics applications are creating substantial Molecular Imaging Market Opportunities. More than 53% of oncology specialists now use molecular imaging biomarkers for treatment monitoring. PSMA PET imaging procedures increased by nearly 44% globally between 2023 and 2025 due to rising prostate cancer prevalence. Approximately 61% of precision medicine programs integrate molecular imaging data into therapy selection processes. Research institutions initiated over 110 theranostic clinical studies during 2024 involving targeted radionuclide therapies. Hybrid imaging systems with AI-based analytics improved lesion detection sensitivity by approximately 29%. Asia-Pacific countries expanded nuclear medicine investments by nearly 31%, supporting future imaging infrastructure development. Molecular Imaging Market Outlook suggests growing partnerships between radiopharmaceutical developers and imaging equipment manufacturers.

CHALLENGE

"High operational and compliance complexities"

Operational challenges continue affecting the Molecular Imaging Market Size. Nearly 46% of healthcare facilities cited isotope handling regulations as a major barrier to imaging expansion. PET tracers require specialized logistics because several isotopes possess half-lives below 120 minutes. Approximately 38% of imaging providers faced scheduling delays linked to radiopharmaceutical shortages during 2024. Installation timelines for advanced molecular imaging systems range from 8 to 14 months due to shielding and regulatory requirements. Around 41% of diagnostic centers reported cybersecurity concerns related to AI-enabled imaging platforms. Equipment calibration and quality assurance procedures consume approximately 19% of annual operational imaging budgets. Molecular Imaging Industry Analysis also indicates that reimbursement variability across regions limits consistent adoption rates.

Segmentation Analysis

The Molecular Imaging Market is segmented by type and application, with PET-based technologies dominating global adoption. PET imaging systems account for approximately 64% of total molecular imaging installations, while oncology applications contribute nearly 72% of procedural demand. Neurology represents around 13%, followed by cardiovascular imaging at approximately 9%. More than 58% of imaging facilities prioritize hybrid systems such as PET/CT due to improved anatomical and metabolic visualization. Molecular Imaging Market Trends indicate increasing use of PSMA imaging and AI-integrated workflows.

Download FREE Sample to learn more about this report.

By Type

PSMA PET Imaging: PSMA PET Imaging gained significant momentum due to increasing prostate cancer diagnosis rates worldwide. Approximately 1.5 million new prostate cancer cases were identified globally in 2024, with PSMA PET scans utilized in nearly 61% of advanced-stage evaluations. This imaging segment contributes approximately 18% of total molecular imaging oncology procedures. More than 52 countries approved PSMA-targeted tracers for clinical use. Detection sensitivity in recurrent prostate cancer cases improved by approximately 35% compared to conventional imaging techniques. Nearly 46% of nuclear medicine centers added PSMA PET capabilities between 2023 and 2025.

FDG PET Imaging: FDG PET Imaging remains the dominant molecular imaging segment, accounting for nearly 69% of total tracer utilization globally. More than 24 million FDG PET procedures were performed during 2024, largely in oncology diagnostics. FDG PET systems are widely used across over 7,000 hospitals and imaging centers worldwide. Approximately 74% of lymphoma and lung cancer evaluations involve FDG PET imaging. Detection accuracy for metastatic disease improved by nearly 31% using FDG-based imaging compared to standalone CT scanning. Around 63% of oncology imaging workflows utilize FDG tracers for therapy monitoring. Molecular Imaging Market Research Report data indicates that digital PET systems improved FDG image sensitivity by approximately 27%.

Other: Other molecular imaging types include SPECT imaging, amyloid PET imaging, and novel radionuclide tracers. These technologies account for approximately 13% of global molecular imaging utilization. Amyloid PET imaging procedures increased by nearly 26% during 2024 due to rising Alzheimer’s disease diagnosis initiatives. More than 320 clinical trials investigated novel radiotracers for inflammatory and neurological diseases. SPECT imaging remains relevant in approximately 49% of cardiac imaging procedures globally. Around 37% of research institutions focus on developing non-oncology molecular imaging tracers.

By Application

Oncology: Oncology dominates the Molecular Imaging Market Share with approximately 72% contribution to overall imaging procedures. More than 20 million new cancer diagnoses globally increased demand for PET-based diagnostics during 2024. Approximately 79% of tertiary oncology hospitals integrated hybrid PET/CT systems into cancer staging workflows. Molecular imaging improves detection sensitivity for metastatic tumors by nearly 34%. Breast cancer, lung cancer, colorectal cancer, and prostate cancer collectively account for approximately 67% of oncology molecular imaging procedures. Over 58% of oncologists use molecular imaging data for treatment response evaluation.

Cardiovascular Diseases: Cardiovascular disease applications contribute approximately 9% of the Molecular Imaging Industry Analysis. More than 620 million individuals worldwide are affected by cardiovascular disorders, increasing demand for myocardial perfusion imaging. SPECT and PET imaging account for nearly 54% of advanced cardiac diagnostic procedures. PET myocardial blood flow assessment improves diagnostic precision by approximately 29% compared to traditional stress testing. Around 43% of cardiac imaging centers adopted hybrid PET/CT systems for coronary artery disease evaluation during 2024. Molecular imaging is increasingly utilized for inflammatory vascular disease assessment and viability studies in heart failure patients.

Neurology: Neurology applications represent approximately 13% of the Molecular Imaging Market Size. More than 55 million individuals globally live with dementia-related disorders, driving adoption of amyloid and tau PET imaging technologies. Approximately 41% of neurological research hospitals expanded PET imaging programs between 2023 and 2025. Molecular imaging improves early Alzheimer’s disease detection by nearly 32% compared to structural MRI alone. Parkinson’s disease imaging procedures increased by approximately 19% during 2024. Over 36% of neurology clinical trials incorporated molecular imaging biomarkers for treatment evaluation. Molecular Imaging Market Trends show growing integration of AI in neuroimaging interpretation.

Respiratory Diseases: Respiratory disease applications account for approximately 4% of molecular imaging utilization globally. Lung cancer diagnosis contributes nearly 71% of respiratory molecular imaging procedures. PET imaging sensitivity for pulmonary lesion detection exceeds conventional imaging by approximately 28%. More than 2.4 million lung cancer cases annually increase imaging demand worldwide. Around 39% of pulmonary specialty hospitals adopted advanced PET imaging systems for inflammatory lung disease evaluation. Molecular imaging also supports tuberculosis and chronic obstructive pulmonary disease research programs. Approximately 23% of respiratory imaging studies involve novel radiotracer development.

Others: Other applications include infectious diseases, autoimmune disorders, and endocrine disease imaging, contributing approximately 2% of the Molecular Imaging Market Outlook. More than 110 clinical trials investigated molecular imaging applications beyond oncology and neurology during 2024. Approximately 29% of endocrine tumor evaluations involve molecular imaging procedures. Infection imaging with radiolabeled tracers improved localization accuracy by nearly 21%. Autoimmune disease molecular imaging studies increased by approximately 18% between 2023 and 2025. Research institutions continue expanding imaging biomarker development for rare diseases and inflammatory conditions.

Regional Outlook

The Molecular Imaging Market demonstrates strong regional variation driven by healthcare infrastructure, cancer prevalence, and nuclear medicine investments. North America accounts for nearly 39% of global imaging procedures due to advanced PET/CT adoption and over 2,400 installed systems. Europe contributes approximately 28% through strong research programs and radiopharmaceutical development. Asia-Pacific holds around 24% share supported by expanding hospital infrastructure and rising oncology cases, while Middle East & Africa represent nearly 9% with increasing diagnostic modernization initiatives.

Download FREE Sample to learn more about this report.

North America

North America dominates the Molecular Imaging Market with approximately 39% share of global procedure volumes. The United States alone accounts for over 41% of worldwide PET imaging procedures. More than 2,400 PET/CT systems and approximately 220 cyclotron facilities operate across North America. Canada expanded nuclear medicine imaging capacity by nearly 17% between 2023 and 2025. Approximately 73% of advanced oncology centers in the region utilize AI-integrated molecular imaging systems.

The region conducts over 19 million nuclear medicine procedures annually, with oncology representing nearly 74% of applications. FDG PET imaging remains dominant with approximately 68% tracer utilization share. More than 58% of healthcare institutions upgraded imaging software platforms during 2024 to improve image reconstruction efficiency. Molecular Imaging Market Analysis indicates that digital PET adoption increased by approximately 29% across tertiary hospitals.

Research activity remains strong, with more than 340 ongoing molecular imaging clinical trials in North America during 2025. Approximately 46% of precision medicine programs integrate molecular imaging biomarkers. PSMA PET imaging adoption expanded by nearly 39% due to increasing prostate cancer incidence. Hybrid PET/MRI installations increased by approximately 18% across academic medical centers.

Europe

Europe accounts for approximately 28% of the Molecular Imaging Market Share, supported by extensive nuclear medicine infrastructure and research investments. Germany, France, and the United Kingdom collectively represent nearly 54% of European molecular imaging procedures. Over 1,900 PET/CT systems are operational across Europe, while more than 120 isotope production facilities support radiopharmaceutical demand.

Approximately 63% of European oncology hospitals utilize hybrid molecular imaging for therapy planning and disease monitoring. FDG PET imaging contributes nearly 66% of tracer usage, while PSMA imaging accounts for approximately 16%. Digital imaging system adoption increased by nearly 24% between 2023 and 2025. Molecular Imaging Industry Report findings indicate that AI-assisted image interpretation improved workflow efficiency by approximately 21%.

Europe also demonstrates strong research participation, with over 280 molecular imaging clinical studies active during 2024. Approximately 37% of imaging centers invested in advanced neuroimaging technologies for dementia diagnostics. Neurology applications contribute around 15% of regional molecular imaging procedures. More than 48% of European imaging providers participate in collaborative radiopharmaceutical research initiatives. Molecular Imaging Market Opportunities are increasing due to expanding theranostic applications.

Asia-Pacific

Asia-Pacific represents approximately 24% of the global Molecular Imaging Market Size and continues experiencing rapid infrastructure expansion. China, Japan, South Korea, and India account for nearly 71% of regional imaging procedures. More than 1,600 PET/CT systems are operational across Asia-Pacific, with installations increasing by approximately 22% during 2024.

Cancer prevalence remains a major driver, with over 10 million regional cancer cases diagnosed annually. Approximately 61% of tertiary hospitals in developed Asia-Pacific economies utilize molecular imaging technologies for oncology diagnostics. FDG PET imaging contributes nearly 71% of total tracer utilization in the region. PSMA PET adoption increased by approximately 33% between 2023 and 2025.

Government healthcare modernization programs accelerated imaging investments, with approximately 42% of new tertiary hospitals integrating hybrid imaging technologies. AI-enabled molecular imaging software adoption increased by nearly 27%. Japan and South Korea collectively contribute approximately 39% of regional research activities in molecular imaging. Molecular Imaging Market Trends also show rising demand for neurology imaging due to aging population demographics, with dementia imaging procedures increasing by approximately 19%.

Middle East & Africa

Middle East & Africa account for approximately 9% of the Molecular Imaging Market Outlook, supported by gradual healthcare infrastructure expansion. Gulf Cooperation Council countries contribute nearly 58% of regional imaging procedure volumes. More than 340 PET/CT systems are operational across the region, with installations increasing by approximately 14% during 2024.

Oncology applications represent approximately 69% of molecular imaging utilization in the region. Saudi Arabia and the United Arab Emirates account for nearly 47% of advanced imaging infrastructure investments. Approximately 36% of tertiary hospitals adopted AI-assisted imaging analysis systems. Molecular Imaging Market Research Report findings indicate that radiopharmaceutical imports increased by approximately 18% due to rising imaging demand.

Africa continues facing infrastructure challenges, with nearly 41% of countries lacking adequate cyclotron facilities. However, diagnostic imaging programs expanded by approximately 16% between 2023 and 2025. Neurology imaging procedures increased by nearly 11%, supported by expanding academic research programs. More than 29% of regional healthcare investments targeted cancer diagnostics and nuclear medicine infrastructure modernization.

List of Top Molecular Imaging Companies

• General Electric Company – Holds approximately 19% share of global molecular imaging equipment installations with more than 3,000 PET and hybrid imaging systems deployed worldwide.
• Siemens Healthineers Inc. – Accounts for nearly 17% of molecular imaging system adoption globally and supports over 2,600 installed hybrid imaging platforms across hospitals and diagnostic centers.

Investment Analysis and Opportunities

The Molecular Imaging Market continues attracting substantial investments due to growing demand for precision diagnostics and theranostic medicine. Approximately 44% of healthcare infrastructure investments in advanced diagnostics during 2024 included molecular imaging technologies. More than 95 new radiotracer research programs were initiated globally between 2023 and 2025. Private-sector investment in AI-assisted molecular imaging software increased by approximately 31%. Asia-Pacific countries expanded nuclear medicine infrastructure spending by nearly 28%, supporting installation of over 350 new PET imaging systems.

Approximately 52% of imaging startups focused on AI-based lesion analysis and automated image reconstruction technologies. Academic institutions and biotechnology firms initiated more than 140 collaborative molecular imaging research projects globally. Theranostic applications remain a major investment area, particularly for prostate and neuroendocrine cancer diagnostics. PSMA-targeted imaging development programs increased by approximately 38%. More than 47% of pharmaceutical companies involved in oncology pipelines integrated molecular imaging biomarkers into clinical trials. Molecular Imaging Market Opportunities are also expanding in neurological imaging, with amyloid PET research studies increasing by approximately 24%. Hybrid PET/MRI systems are receiving higher investment allocation due to improved soft tissue imaging capabilities.

New Product Development

New product development in the Molecular Imaging Market focuses on digital PET systems, AI-enabled imaging software, and targeted radiopharmaceuticals. Approximately 36% of newly launched molecular imaging platforms during 2024 incorporated deep learning reconstruction technologies. Digital detector sensitivity improved by nearly 29% compared to earlier analog PET systems. Manufacturers introduced compact PET scanners with approximately 18% lower space requirements for outpatient imaging centers. More than 41 new radiopharmaceutical tracers entered clinical evaluation between 2023 and 2025. PSMA-targeted tracers demonstrated lesion detection improvements of approximately 32% in prostate cancer imaging studies.

Hybrid imaging innovation accelerated, with PET/MRI systems reducing radiation exposure by approximately 21% compared to PET/CT procedures. Around 48% of product development initiatives focused on workflow automation and cloud-based image analytics. AI-supported imaging platforms reduced scan interpretation time by nearly 26%. Neurological imaging innovations also expanded, with amyloid and tau imaging agents improving Alzheimer’s disease detection sensitivity by approximately 23%. Approximately 34% of imaging manufacturers prioritized portable and mobile imaging solutions for regional healthcare accessibility. Molecular Imaging Market Forecast data indicates continued emphasis on personalized diagnostics and precision imaging technologies.

Five Recent Developments (2023-2025)

• In 2024, Siemens Healthineers Inc. expanded digital PET/CT deployment by approximately 22% across oncology centers, improving scan sensitivity by nearly 28%.
• In 2025, General Electric Company introduced AI-assisted molecular imaging software reducing image reconstruction times by approximately 31%.
• During 2024, Canon Inc. enhanced hybrid imaging systems with advanced detector technologies improving lesion visualization accuracy by approximately 19%.
• In 2023, Bruker Corporation expanded preclinical molecular imaging research platforms supporting over 17% more imaging throughput capacity.
• During 2025, Thermo Fisher Scientific increased radiopharmaceutical manufacturing capabilities by approximately 24% to support expanding oncology imaging demand.

Report Coverage of Molecular Imaging Market

The Molecular Imaging Market Report provides extensive analysis of imaging technologies, radiopharmaceutical trends, clinical applications, and regional infrastructure developments. The report evaluates more than 25 countries and analyzes over 70 imaging manufacturers and radiopharmaceutical suppliers. Approximately 64% of the assessment focuses on PET-based imaging technologies due to their dominant clinical adoption.

The Molecular Imaging Market Research Report covers segmentation by type, application, and region, including oncology, neurology, cardiovascular disease, respiratory disease, and emerging diagnostic areas. Oncology contributes approximately 72% of analyzed imaging utilization, while neurology represents nearly 13%. More than 140 clinical research studies and imaging innovation programs were assessed during report preparation.

The report also evaluates AI integration trends, with approximately 59% of imaging centers implementing machine learning-assisted diagnostics. Over 95 radiotracer development programs and more than 110 theranostic clinical studies were reviewed. Regional coverage includes infrastructure analysis of over 8,500 imaging facilities globally. Molecular Imaging Industry Analysis additionally examines digital PET adoption, hybrid imaging expansion, isotope supply chain developments, and regulatory frameworks affecting global molecular imaging deployment.